Atreca, Inc. (BCEL)
Chart Events
Performance Outlook
| Previous Close | 2.6500 |
| Open | 2.6500 |
| Bid | 2.6500 x 1100 |
| Ask | 2.6600 x 1300 |
| Day's Range | 2.6000 - 2.7800 |
| 52 Week Range | 1.5100 - 7.0000 |
| Volume | |
| Avg. Volume | 289,766 |
| Market Cap | 98.078M |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7900 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.89 |
- Simply Wall St.
We're A Little Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2022 and provided an overview of recent developments. "While we took steps during the second quarter to extend our cash runway through the end of 2023
- GlobeNewswire
Atreca to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate at the following upcoming investor conferences: Wedbush PacGrow 2022 Healthcare Conference August 9-10, 2022Panel Discussion: For Your IOnly - Progress, Challenges in Immuno-Oncolog
